Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "Chronic Rejection Series: Heart Cardiac Allograft Vasculopathy".

Transplantation·2026
Same author

Novel CNNM2 variant causing hypomagnesemia and early-onset calcium pyrophosphate deposition disease: A case report.

Joint bone spine·2025
Same author

Answer to the Comments of H. Daungsupawong et al. About the Study Entitled Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID-19 Vaccination in Heart Transplant Recipients.

Clinical transplantation·2025
Same author

Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID-19 Vaccination in Heart Transplant Recipients.

Clinical transplantation·2025
Same author

Identifying a predictive level of serum C-terminal telopeptide associated with a low risk of medication-related osteonecrosis of the jaw secondary to oral surgery: A systematic review and meta-analysis.

PloS one·2025
Same author

The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab.

Arthritis research & therapy·2025

Related Experiment Video

Updated: May 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

[The cardiologist and immunosuppressive therapy].

Pierre Ambrosi1, Pierre Lafforgue

  • 1Hôpital de la Timone, service de cardiologie, 13385 Marseille, France. pierre.ambrosi@ap-hm.fr

Presse Medicale (Paris, France : 1983)
|April 24, 2012
PubMed
Summary

Cardiologists must monitor patients on immunosuppressive therapy, especially those with heart failure. While TNF inhibitors are generally contraindicated in severe heart failure, they may be used cautiously in milder cases with close cardiac follow-up.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Context:

  • Cardiologists play a crucial role in managing patients undergoing immunosuppressive therapy.
  • Specific considerations arise for patients with cardiac conditions, including heart failure and hypertension.

Purpose:

  • To outline the cardiac monitoring requirements for patients on immunosuppressive therapy.
  • To detail contraindications and precautions for using TNF inhibitors in heart failure.
  • To guide the management of immunosuppression-induced arterial hypertension.

Summary:

  • Tumor Necrosis Factor (TNF) inhibitors are contraindicated in NYHA Class III-IV heart failure, but etanercept may be an exception.
  • For milder heart failure, TNF inhibitors can be used if no alternatives exist, requiring cardiac follow-up.

Related Experiment Videos

Last Updated: May 23, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

  • Cyclosporine and tacrolimus are nephrotoxic and hypertensive; calcium-blockers and renin-angiotensin inhibitors are first-line for hypertension.
  • Calcium-blockers can cause edema and increase calcineurin inhibitor levels; combined use with cyclosporine may lead to gingival hypertrophy and gynecomastia.

    • Impact:

    • Provides essential guidance for cardiologists managing complex patient populations.
    • Aims to optimize immunosuppressive therapy while minimizing cardiovascular risks.
    • Contributes to safer and more effective patient care by highlighting drug interactions and side effects.